3D bioprinting as an emerging standard for cancer modeling and drug testing.
Sign Up to like & getrecommendations! Published in 2022 at "Folia medica"
DOI: 10.3897/folmed.64.e73419
Abstract: Neoplastic diseases are a leading cause of death worldwide accounting for 10 million mortalities in 2020. Despite constantly revised and improved therapeutic regimens, the number of fatal cases increases annually. Therefore, better preclinical models are… read more here.
Keywords: cancer modeling; standard cancer; emerging standard; tumor ... See more keywords